Negative Feedback Regulation: Sermorelin-induced growth hormone release is subject to negative feedback regulation involving somatostatin, a neurohormone that inhibits further hGH secretion
Some performance-oriented protocols may include a second dose in the morning
The consultation process includes assessment of symptoms commonly associated with growth hormone deficiency, such as decreased energy levels, reduced muscle mass, increased body fat, sleep disturbances, and diminished recovery capacity
Disclaimer: this product is not approved for medical use and is not intended to diagnose, treat, or prevent any disease

Contraindications and Precautions Do NOT use AOD-9604 if you: Are pregnant, trying to conceive, or breastfeeding (no safety data in pregnancy/lactation) Have active cancer or history of malignancy (peptide effects on existing cancer unknown) Are under 18 years of age (pediatric safety not established) Have known hypersensitivity to peptides or benzyl alcohol (in bacteriostatic water) Have severe kidney or liver disease without physician clearance Use with caution and enhanced monitoring if you have: Diabetes or glucose metabolism disorders (monitor blood sugar closely despite no expected impact) Cardiovascular disease (comprehensive cardiac evaluation recommended) Thyroid disorders (monitor thyroid function during therapy) History of migraines (may increase headache frequency in susceptible individuals) Drug Interactions Limited formal drug interaction studies exist for AOD-9604